imerge update: continuous transfusion independence & disease modification with imetelstat in lr-mds
Published 1 year ago • 241 plays • Length 1:44Download video MP4
Download video MP3
Similar videos
-
2:51
analysis of the imerge trial: the disease-modifying potential of imetelstat in lr-mds
-
1:25
the recent approval of imetelstat in lr-mds based on results of the imerge trial
-
4:32
recent advances in the treatment of lr-mds: commands and imerge trial data
-
2:05
does imetelstat increase the need for platelet transfusions & growth factors in pts with lr-mds?
-
1:45
a phase ii study of elritercept for lower-risk mds
-
1:39
update on a phase i/ii study of ziftomenib in patients with r/r aml
-
4:06
a phase ii trial of intermittent treatment strategies for ndmm to avoid asct
-
1:17
phase ii study of tosedostat in mds
-
2:04
introducing a phase ib/ii trial to evaluate tasquinimod for the treatment of myelofibrosis
-
8:32
upgrade your vision - extended version
-
1:07
the second revision of the international staging system for os in mm
-
2:02
unmet needs in high-risk mds and future therapeutic strategies
-
3:23
final long-term follow-up results of the relaza2 study: mrd-guided treatment with aza in mds and aml
-
3:17
pre-mds states: novel therapeutic approaches, and determining appropriate trial endpoints
-
1:50
criteria for the diagnosis of accelerated/blast phase mpn and challenges clinicians may face
-
1:32
blast-phase mpns: a major unmet need in the field
-
2:39
treating and managing blast-phase mpns: a major unmet need
-
1:36
integrated sequencing utilized in a timely and impactful manner in aml/mds
-
1:23
insights into the management and treatment of accelerated/blast-phase mpns